Background {#Sec1}
==========

Abdominal aortic aneurysm (AAA), defined as the aortic diameter \> 3.0 cm, is a cardiovascular system disease that is characterized by aortic dilation that exceeds the normal aortic diameter by more than 50%. AAA dilatation will lead to rupture of the aorta, which results in bleeding. Generally, it is asymptomatic until the rupture event occurs \[[@CR1]\]. Additionally, AAA is common in adult patients, especially elderly men, and leads to severe complications \[[@CR2]--[@CR4]\]. Up to now, the etiology of AAA remains unclear. It is noted that some clinical risk factors including smoking history, advanced age, family history, hypertension, hyperlipidaemia, atherosclerosis, chronic obstructive pulmonary disease are remarkably related to AAA \[[@CR3], [@CR5]--[@CR7]\]. It is also observed that the intricate interplay of apoptosis, inflammation and matrix degradation is involved in the development of this disorder \[[@CR8]--[@CR10]\]. Anyway, the pathophysiology of AAA is complex, but fundamentally aneurysm comes from the vessel wall structural integrity loss and the vessel wall weakening. It is pointed out that vascular smooth muscle cells are the critical cell type involved in the development of AAA \[[@CR11]\].

In a word, AAA is a common and late onset disease, which can rupture with a high mortality if not treated. In some clinical practice, there is no effective treatment other than surgical approaches to repair AAA \[[@CR12]\]. And endovascular aneurysm repair has improved detection and lower mortality rates of AAA \[[@CR13]--[@CR17]\]. However, morbidity and mortality after surgery are still common \[[@CR18], [@CR19]\]. Therefore, understanding the genetic architecture and pathological mechanism of the disease may provide valuable information for elucidation of pathogenic mechanisms and signal pathways in AAA and the discovery of potential biomarkers and drug targets in AAA diagnosis and non-surgical treatment therapy.

In this study, we tried to find differentially expressed genes (DEGs) in AAA by integrated analysis. Then, functional enrichment analysis including Gene Ontology (GO) and Kyoto Encyclopedia of Genes Genomes (KEGG) was used to investigate the biological function of DEGs followed by transcriptional factors (TFs) network an d protein-protein interaction (PPI) network construction of top 20 DEGs (10 up-regulated and 10 down-regulated). Immunohistochemical (IHC) staining was applied to validate the expression of candidate DEGs. Finally, receiver operating characteristic (ROC) analyses was applied to analyze diagnosis ability of identified DEGs. Our study may be helpful in understanding the pathogenic mechanism and finding valuable diagnosis biomarkers and therapy drug in AAA.

Methods {#Sec2}
=======

Datasets {#Sec3}
--------

In this study, we searched datasets from the Gene Expression Omnibus (GEO) database ([http://www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo)) with the keywords abdominal aortic aneurysm \[All Fields\] AND ("gse"\[Filter\] AND "Homo sapiens"\[Organism\]). The study type was described as "expression profiling by array." All selected datasets were genome-wide expression data of AAA group and/or normal group tissue samples. Those standardized or primary datasets were included in this study. Finally, a total of 3 datasets including GSE7084, GSE47472 and GSE57691 were screened, which was shown in Table [1](#Tab1){ref-type="table"}.Table 1Three datasets in GEOGEO accessionAuthorPlatformSamples(P:N)YearGSE7084Tromp GGPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array;GPL2507Sentrix Human-6 Expression BeadChip7:82007GSE47472Biros EGPL10558Illumina HumanHT-12 V4.0 expression beadchip14:82013GSE57691Biros EGPL10558Illumina HumanHT-12 V4.0 expression beadchip49:102015*P* patients, *N* normal individual

Analysis of DEGs {#Sec4}
----------------

Raw expression data of AAA patients in this study were downloaded. Limma and metaMA packages were used to identify the DEGs. And the inverse normal method was used to combine the *p* value in metaMA. The false discovery rate (FDR) was performed for multiple testing corrections of raw p value through the Benjamin and Hochberg method \[[@CR20], [@CR21]\]. The threshold of DEGs was set as FDR \< 0.01.

Functional annotation analyses of DEGs {#Sec5}
--------------------------------------

To obtain the biological function and signaling pathways of DEGs, the Metascape software was used for Gene Ontology (GO, <http://www.geneontology.org/>) annotation and Kyoto Encyclopedia of Genes Genomes (KEGG, <http://www.genome>. jp/kegg/pathway.html) pathway enrichment of DEGs. The threshold of GO function and KEGG pathway of DEGs was all set as FDR \< 0.05.

PPI network construction {#Sec6}
------------------------

It is useful for understanding the molecule mechanism of AAA to study the interactions between proteins. In order to gain insights into the interaction between proteins encoded by DEGs and other proteins, the database of BioGRID (<http://thebiogrid.org>) was used to retrieve the predicted interactions between top 20 proteins encoded by DEGs (10 up-regulated and 10 down-regulated) and other proteins. The PPI network was generated by the Cytoscape Software (<http://cytoscape.org/>). A node in the PPI network denotes protein, and the edge denotes the interactions.

Analysis of potential TFs to target DEGs {#Sec7}
----------------------------------------

TFs play a critical role in regulating gene expression. We downloaded the TFs in the human genome and the motifs of genomic binding sites from the TRANSFAC. Moreover, the 2 KB sequence in the upstream promoter region of DEGs was downloaded from UCSC (<http://www.genome.ucsc.edu/cgi-bin/hgTables>). Target sites of potential TFs were then distinguished. Finally, the transcriptional regulatory network was visualized by Cytoscape software.

Immunohistochemical (IHC) staining for CCR7 and PDGFA {#Sec8}
-----------------------------------------------------

In this study, a patient with AAA and a normal individual was enrolled for the IHC experiment. The 5 μm slides were incubated with anti CCR7 primary rabbit anti-human polyclone antibody (1:500 dilution; abcam) and anti PDGFA primary rabbit anti-human polyclone antibody (1:500 dilution; Invitrogen) followed incubated with peroxidase conjugated goat anti-rabbit secondary antibody (1:200 dilution; Vector). For color visualization, diaminobenzidine (DAB) substrate (Vector) was applied. The staining area was analyzed by the software of Image Pro-plus 6.0 (Media Cybernetics Corporation, arrendale, PA, USA), and quantified by the IHC staining score (intensity score × positive rate score). The negative (−), positive (+), positive (++), positive (+++) of intensity scores represented 0, 1, 2 and 3, respectively. The positive rate score including negative, 1--25%, 26--50%, 51--75% and 76--100% represented 0, 1, 2, 3 and 4, respectively. IHC staining score of 0, 1\~ 4, 5\~ 8 and 9\~ 12 represented negative, slight positive, moderate positive and strong positive, respectively.

All patients provided written informed consent with the approval of the ethics committee of the First Affiliated Hospital of Wenzhou Medical University (2017147).

Receiver operating characteristic analyses {#Sec9}
------------------------------------------

By using pROC package in R language we performed the receiver operating characteristic (ROC) analyses to assess the diagnostic value of DEGs (NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA) in AAA. The area under the curve (AUC) was calculated and the ROC curve was generated.

Results {#Sec10}
=======

DEGs analysis {#Sec11}
-------------

Raw expression profiles of AAA patients were downloaded from the data portal of the GEO database. A total of 1199 DEGs were identified as the threshold at FDR \< 0.01, consisting of 188 up-regulated genes and 1011 down-regulated genes. The top 10 up- and down-regulated DEGs are listed in Table [2](#Tab2){ref-type="table"}. The heat map of the top 50 DEGs is shown in Fig. [1](#Fig1){ref-type="fig"}.Table 2Top 10 up- and down-regulated DEGsGene IDGene SymbolFDRCombined.ESGene IDGene SymbolFDRCombined.ESUp-regulated genesDown-regulated genes115,362GBP52.46E-071.7187287035154PDGFA2.01E-10−2.167967973043HBB5.91E-071.7799621882063NR2F63.18E-09−2.071097053040HBA21.45E-061.7342338721459CSNK2A23.18E-09−2.0099478023560IL2RB4.69E-061.43474671928,999KLF156.12E-09−2.0264429554753NELL28.52E-061.3953267220TRPC17.99E-09−1.9197708395743PTGS21.01E-051.37816210781,493SYNC2.20E-08−1.98029975684,658ADGRE31.03E-051.4239792147704ZBTB162.31E-08−2.0233437238972MGAM1.37E-051.372006422116,151FAM210B4.86E-08−1.86973248854,504CPVL1.49E-051.44549942308FOXO14.94E-08−1.8415281661236CCR71.66E-051.33531711158,499ZNF4625.47E-08−2.004150438*FDR* false discovery rate, *Combined.ES* combined effect sizeFig. 1The heat map of top 50 DEGs. The diagram presents the result of a two-way hierarchical clustering of the top 50 DEGs and samples. The clustering is constructed using the complete-linkage method together with the Euclidean distance. Each row represents a DEG and each column, a sample. The DEG clustering tree is shown on the right. The colour scale illustrates the relative level of DEG expression: red, below the reference channel; green, higher than the reference

Functional and pathway enrichment analyses of DEGs {#Sec12}
--------------------------------------------------

To investigate the biological function of the identified DEGs in AAA, GO term and KEGG pathway enrichment analyses was performed. In GO term and KEGG pathway enrichment analyses, circulatory system development, muscle structure development and translational initiation were the most significant enrichment in biological process (Fig. [2](#Fig2){ref-type="fig"}); Oxidoreductase activity, electron carrier activity, protein domain specific binding were the most notable enrichment in molecular function (Fig. [3](#Fig3){ref-type="fig"}); Mitochondrial part, focal adhesion and intracellular ribonucleoprotein complex were the most significant enrichment in cellular component (Fig. [4](#Fig4){ref-type="fig"}). The top 10 GO terms of DEGs are shown in Table [3](#Tab3){ref-type="table"}, and the KEGG enrichment signal pathways of DEGs shown in Table [4](#Tab4){ref-type="table"}. The vascular smooth muscle contraction and pathways in cancer that were significantly related to AAA are shown in Fig. [5](#Fig5){ref-type="fig"} and Fig. [6](#Fig6){ref-type="fig"}, respectively.Fig. 2Significantly enriched biological processes of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeplyFig. 3Significantly enriched molecular functions of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeplyFig. 4Significantly enriched cellular components of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeplyTable 3Top 10 GO terms of DEGsGO IDGO termList in termLog pBiological process GO:0072359circulatory system development101/913−10.6462 GO:0061061muscle structure development67/563−8.4846 GO:0006413translational initiation40/268−7.9403 GO:0008285negative regulation of cell proliferation70/643−7.2506 GO:0060548negative regulation of cell death89/910−6.8694 GO:0003170heart valve development12/34−6.8435 GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway89/928−6.4948 GO:0070372regulation of ERK1 and ERK2 cascade34/238−6.3893 GO:0006935chemotaxis81/860−5.6514 GO:0060485mesenchyme development32/237−5.5128Molecular function GO:0016491oxidoreductase activity75/719−6.9626 GO:0009055electron carrier activity21/112−6.0854 GO:0019904protein domain specific binding61/623−4.9011 GO:0008092cytoskeletal protein binding74/810−4.7540 GO:0032403protein complex binding82/928−4.6775 GO:0003735structural constituent of ribosome27/210−4.3707 GO:1,901,681sulfur compound binding27/232−3.6356 GO:0016453C-acetyltransferase activity3/4−3.1832 GO:0016634oxidoreductase activity, acting on the CH-CH group of donors, oxygen as acceptor4/9−3.0208 GO:0008565protein transporter activity14/98−2.9919 GO:0016491oxidoreductase activity75/719−6.9626Cellular component GO:0044429mitochondrial part109/943−12.6878 GO:0005925focal adhesion55/391−9.6768 GO:0030529intracellular ribonucleoprotein complex70/710−5.6423 GO:0005759mitochondrial matrix45/404−5.1349 GO:0015629actin cytoskeleton46/442−4.4798 GO:0005901caveola14/76−4.1752 GO:0030663COPI-coated vesicle membrane6/17−3.6750 GO:0044455mitochondrial membrane part22/173−3.6079 GO:0090665glycoprotein complex6/21−3.1162 GO:0044451nucleoplasm part59/708−2.9012List in term: the number of DEGs on the total number of genes in GO term*Log p* logarithm processing of *p* valueTable 4The KEGG enrichment signal pathways of DEGsKEGG IDKEGG termList in termLog pGene listhsa03010Ribosome22/135−6.5000FAU,RPL7,RPL9,RPL24,RPL27,RPL30,RPL35A,RPS6,RPS21,UBA52,MRPL33,MRPL19,MRPL18,MRPL22,MRPS16,RSL24D1,MRPL20,MRPS15,MRPS6,MRPS5,MRPL1,MRPL24hsa00640Propanoate metabolism10/32−5.9097ACAT1,ACAT2,LDHA,LDHB,ALDH6A1,MUT,PCCA,SUCLG2,HIBCH,ACSS2,ALDH2,ALDH3A2,HADH,HMGCL,ACO1,GCSH,HOGA1,ESD,PFKM,PRPS2,PHGDH,L2HGDHhsa04510Focal adhesion23/202−4.1028ACTN1,CAPN2,CAV2,COL4A1,FLNC,HRAS,ITGA7,LAMA5,LAMC1,PPP1R12A,PDGFA,PDGFRB,MAPK3,PTEN,ROCK1,THBS2,ITGA10,ROCK2,ITGA11,PARVA,PDGFC,TLN2,SHC4,FGF13,MYH10,WASL,ARPC1A,ARHGEF12,GNG12,PIP4K2Chsa04270Vascular smooth muscle contraction16/120−3.8133ADCY3,AGTR1,CALD1,EDNRA,GNA11,KCNMB1,MYH11,MYL6,PPP1R12A,MAPK3,PTGIR,ROCK1,ROCK2,RAMP1,ARHGEF12,PPP1R14Ahsa00071Fatty acid degradation9/44−3.7701ACADL,ACAT1,ACAT2,ADH1A,ADH1B,ALDH2,ALDH3A2,ECI1,HADH,ACYP2,LDHA,LDHB,ACSS2,PFKM,PGM1hsa03020RNA polymerase7/31−3.3221POLR2C,POLR2F,POLR2G,POLR2H,POLR2I,POLR3F,POLR3C,ADCY3,AK1,GUK1,NME3,PGM1,PRPS2,ENPP4,NME7,AK3,NUDT9,POLE4,NT5C3B,CTPS1hsa05016Huntington's disease20/193−3.1152COX5B,COX6C,COX7A1,COX7B,COX7C,HDAC2,NDUFA4,NDUFA8,NDUFB10,NDUFC1,POLR2C,POLR2F,POLR2G,POLR2H,POLR2I,SOD1,ATP5H,UQCRQ,NDUFA12,NDUFA4L2,UBE2G2,SNCAIP,PINK1,COX17,ATP6V1D,CAPN2,MAPK3,RYR3hsa05200Pathways in cancer33/397−2.9576ADCY3,AGTR1,AR,COL4A1,E2F3,EDNRA,MECOM,FGF13,FOXO1,FZD2,GNA11,GSTP1,MSH6,HDAC2,HRAS,LAMA5,LAMC1,SMAD4,PDGFA,PDGFRB,MAPK3,PTEN,ROCK1,SLC2A1,TCEB1,ZBTB16,FZD3,CCDC6,ROCK2,GNB5,RALBP1,ARHGEF12,GNG12,PDGFChsa05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)10/74−2.6366ACTN1,CACNB3,CDH2,DAG1,GJA1,ITGA7,RYR2,SGCA,ITGA10,ITGA11hsa00520Amino sugar and nucleotide sugar metabolism7/48−2.1749CYB5R3,GMDS,PGM1,PMM1,UAP1,UGDH,UGP2List in term: the number of DEGs on the total number of genes in GO term*Log p* logarithm processing of *p* valueFig. 5Significantly enriched vascular smooth muscle contraction signal pathways of DEGs. The red and green diamond represents the up and down-regulated DEGsFig. 6Significantly enriched pathways in cancer signal pathways of DEGs. The red and green diamond represents the up and down-regulated DEGs

Establishment of TFs-target genes regulatory network {#Sec13}
----------------------------------------------------

In order to study the TFs-target genes regulatory network for AAA, we utilized TRANSFAC to identify TFs regulating the top ten up-regulated or down-regulated DEGs. In the end, we obtained transcriptional regulatory networks comprised of 190 pairs of TFs-genes involving 40 TFs (Fig. [7](#Fig7){ref-type="fig"}). In this network, the top 7 downstream genes covered by most TFs were neural EGFL like 2 (NELL2, degree = 13), C-C motif chemokine receptor 7 (CCR7, degree = 9), maltase-glucoamylase (MGAM, degree = 8), hemoglobin subunit beta (HBB, degree = 8). Five hub TFs were HNF-4 (degree = 10), Oct-1 (degree = 10), Pax-4 (degree = 8), Evi-1 (degree = 6) and Nkx2--5 (degree = 6) (Table [5](#Tab5){ref-type="table"}).Fig. 7The TFs networks of the top 20 DEGs. Diamonds and ellipses represent the TFs and target genes, respectively. The red and green colors represent up-regulation and down-regulation, respectivelyTable 5Top 5 TFs and target genesTFsNumberTarget genesOct-110CCR7, CPVL, CSNK2A2, HBB, IL2RB, MGAM, NELL2, TRPC1, ZBTB16, ZNF462HNF-410CCR7, CPVL, CSNK2A2, HBB, KLF15, MGAM, NELL2, NR2F6, PTGS2, ZNF462Pax-48ADGRE3, CSNK2A2, FAM210B, NELL2, NR2F6, PDGFA, SYNC, ZBTB16Evi-16CPVL, GBP5, HBB, NELL2, PTGS2, ZNF462Nkx2--56CCR7, GBP5, MGAM, NELL2, TRPC1, ZBTB16

PPI network {#Sec14}
-----------

To obtain the interaction between the proteins encoded by DEGs and other proteins, PPI network was explored and visualize by Cytoscape. PPI networks of the top 10 up-regulated and the top 10 down-regulated DEGs were presented in Fig. [8](#Fig8){ref-type="fig"}. As Fig. [8](#Fig8){ref-type="fig"} shows, the network consisted of 539 nodes and 567 edges. The red and green diamonds indicate the up- and down-regulated genes in AAA, respectively. The blue ellipses present the proteins that interacted with those proteins encoded by DEGs. The top three proteins with a high degree were casein kinase 2 alpha 2 (CSNK2A2, degree = 184), zinc finger and BTB domain containing 16 (ZBTB16, degree = 113) and forkhead box O1 (FOXO1, degree = 53).Fig. 8The PPI networks of the top 20 DEGs. All the diamonds are proteins encoded by the top 20 DEGs and the blue ellipses represent other proteins. The red and green colors represent up-regulation and down-regulation, respectively

Validation of CCR7 and PDGFA in AAA {#Sec15}
-----------------------------------

In order to validate the expression of CCR7 and platelet derived growth factor subunit A (PDGFA), we assessed the protein expression of CCR7 and PDGFA in AAA through the immunohistochemistry (Fig. [9](#Fig9){ref-type="fig"} and Fig. [10](#Fig10){ref-type="fig"}). The result showed that CCR7 was obviously up-regulated in AAA compared with the control, which was consistent with the bioinformatic consequence. However, PDGFA was significantly up-regulated in AAA compared with the control, which was not in line with the bioinformatic result.Fig. 9The IHC staining of CCR7 in AAA. CCR7 protein expression level detected by immunohistochemistry and photographs was amplified 10 × 20 multiples. Bar = 100 μm. **a** and **c** were the case samples from two patients with AAA; **b** and **d** were the control sample from two normal individuals. ^\*^*P*\<0.05 vs controlFig. 10The IHC staining of PDGFA in AAA. PDGFA protein expression level detected by immunohistochemistry and photographs was amplified 10 × 20 multiples. Bar = 100 μm. **a** and **c** were the case samples from two patients with AAA; **b** and **d** were the control sample from two normal individuals. ^\*\*^*P*\<0.01 vs control

ROC curve analysis {#Sec16}
------------------

In order to access the discriminatory ability of the NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA among AAA tissues and adjacent non-tumor tissues generated from GEO database, ROC curve analyses were conducted and AUC were calculated. As Fig. [11](#Fig11){ref-type="fig"} shown, the AUC of all these genes was more than 0.8. For AAA diagnosis, the sensitivity and specificity of these genes were very high.Fig. 11The ROC curve analyses of NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA between AAA and healthy controls

Discussion {#Sec17}
==========

In spite of improvement to surgical techniques that have been made in AAA treatment, morbidity and mortality after operations are still common. AAA seriously influences the life quality of patients and brings a heavy burden on the family. Therefore, it is urgent to elucidate AAA pathogenesis mechanism for developing novel diagnose and therapeutic target.

TFs are key regulatory factors in gene expression. The construction of regulatory networks between TFs and target genes is helpful in understanding the biological regulatory mechanism in the development of AAA. In this study, we found NELL2, CCR7, MGAM and HBB were significantly expressed genes with the most degree under the regulation of TFs including HNF-4, Oct-1 and Pax-4. NELL2 is a neural tissue-enriched protein in mammal and it is a receptor for vascular endothelial growth factor-A, which plays an important role in angiogenesis. It is reported that the mRNA expression of NELL2 is up-regulated in benign prostate hyperplasia and prostate cancer \[[@CR22]\]. In addition, NELL2 is regarded as the potential biomarker for bladder cancer \[[@CR23]\]. CCR7 is a pro-inflammatory cytokine and is found in human atherosclerotic plaques \[[@CR24]\]. It is found that expression of CCR7 is dramatically down-regulated in human carotid atherosclerotic plaques \[[@CR25]\]. MGAM is found down-regulated and considered as a candidate serum biomarker in colorectal cancer \[[@CR26]\]. Additionally, MGAM is a significantly mutated gene in lung adenocarcinoma \[[@CR27]\]. HBB is suggested as a potential biomarker in the plasma sample of patients with AAA \[[@CR28]\]. In this study, we found that NELL2, CCR7, MGAM and HBB were up-regulated in the AAA tissues, which played crucial roles in the carcinogenesis of AAA.

The interaction among proteins determines the characteristic of the cell, tissue and individual. The study of PPI is a useful way to find the potential drug target of AAA. Herein, we found three genes including CSNK2A2, ZBTB16 and FOXO1 were for the most degree in the PPI network. CSNK2A2 is found to be correlated with ovarian cancer patient survival. Furthermore, the down-regulation of CSNK2A2 will decrease the proliferation of ovarian cancer cells \[[@CR29]\]. ZBTB16, also called PLZF, plays an important role in oncogenesis and is first identified in acute promyelocytic leukemia \[[@CR30]\]. Based on a microarray study, ZBTB16 is found to be down-regulated in AAA \[[@CR31]\]. FOXO1 is a transcription factor and plays roles in diverse physiological processes including Akt-dependent cell proliferation and apoptosis \[[@CR32]\]. Additionally, FOXO1 is also involved in energy metabolism and autophagy \[[@CR33]\]. In our study, we found down-regulated expression of CSNK2A2, ZBTB16 and FOXO1. It is worth mentioning that ZBTB16 and FOXO1 were also involved in the pathways in cancer according to the KEGG analysis. In addition, PDGFA was one of the top ten down-regulated genes and also involved in the pathways in cancer. PDGFA is expressed in vascular smooth muscle cells and has been involved in migration and proliferation of vascular smooth muscle cells \[[@CR34]\]. Moreover, the importance of PDGFA in the arterial system has been demonstrated on account of that fact that the proliferation of arterial vascular smooth muscle cells was strongly stimulated by PDGFA \[[@CR35]\]. Moreover, an in situ hybridization study has demonstrated mRNA for PDGFA in atherosclerotic plaques \[[@CR36]\]. In this study, we found that PDGFA was down-regulated in AAA. However, the IHC result was not consistent with the bioinformatic analysis. The small sample size may account for the discrepancy. In a word, CSNK2A2, ZBTB16 and FOXO1 played a crucial role in the oncogenesis of AAA and could be considered as drug targets of AAA.

Apart from the cancer signal pathway, vascular smooth muscle contraction was another signal pathway identified that associated with AAA. Vascular smooth muscle cells have been shown to play an important synthetic role in vascular remodeling \[[@CR37], [@CR38]\]. It is pointed out that vascular smooth muscle cells are the main component of the aortic media and the dysfunction plays a key role in different arterial diseases, such as AAA \[[@CR39]\]. In addition, vascular smooth muscle cell activation is the main hallmark of atherosclerosis, which is a risk factor of AAA \[[@CR40]--[@CR43]\]. Several down-regulated genes were significantly involved in the signal pathway, such as AGTR1, CALD1, EDNRA, MYH11, RAMP1, ROCK1 and ROCK2.

Angiotensin II receptor type 1 (AGTR1) is a cardiovascular risk gene. Jones, G. T et al. found that AGTR1 was remarkably associated with AAA \[[@CR44]\]. In addition, the 1166A *\>* C polymorphism in AGTR1 has been demonstrated to be associated with AAA \[[@CR45], [@CR46]\]. It is noted that AGTR1 blockers (ARBs) have been investigated for prevention or delay of aortic dilatation \[[@CR47]\]. It is reported that the expression of caldesmon 1 (CALD1) is increased in aortas, which protects from aneurysm. This suggested that importance of CALD1 in maintaining vascular integrity in AAA. Endothelin receptor type A (EDNRA) is primarily located in the vascular smooth muscle cells and mediates vasoconstriction and proliferation \[[@CR48]\]. It has been reported that EDNRA on chromosome 4q31 is related to intracranial aneurysm \[[@CR49]\]. It is found that heterozygous mutation of myosin heavy chain 11 (MYH11) results in the early and severe decrease in the aortic wall elasticity \[[@CR50]\]. Additionally, it has been demonstrated the relationship between MYH11 genetic and epigenetic and thoracic aortic aneurysms and dissections \[[@CR51], [@CR52]\]. Receptor activity modifying protein 1 (RAMP1) is a member of a family of calcitonin receptor modifying proteins and is thought to play an important role in regulating blood pressure by vascular relaxation. Tsujikawa K et al. found that ramp1-deficient mice exhibited elevated blood pressure \[[@CR53]\]. It is pointed out that the mRNA levels of RAMP1 are decreased in AAA \[[@CR31]\]. It is found that the expression of Rho associated coiled-coil containing protein kinase 1 (ROCK1) and Rho associated coiled-coil containing protein kinase 1 (ROCK2) was increased at the AAA lesion compared with control \[[@CR54]\]. Thus it can be seen that AGTR1, CALD1, EDNRA, MYH11, RAMP1, ROCK1 and ROCK2 played an important role in vascular smooth muscle contraction, which was significantly associated with AAA.

In order to access the discriminatory ability of identified genes in the TFs and PPI network, eight genes including NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA were applied to ROC curve analyses among AAA tissues and adjacent non-tumor tissues in GEO database. Our result showed that the AUC of all these genes was more than 0.8, especially HBB (AUC: 0.906), CSNK2A2 (AUC: 0.945), ZBTB16 (AUC: 0.950), FOXO1 (AUC: 0.940) and PDGFA (AUC: 0.930). This suggested that NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA may have value in diagnosis of the development of AAA.

Conclusions {#Sec18}
===========

In summary, we found a series of DEGs in AAA. Among which, eight genes including NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA could be used for the diagnosis biomarkers of AAA. Especially, CSNK2A2, ZBTB16 and FOXO1 could be considered as drug targets in the therapy of AAA. In addition, vascular smooth muscle contraction was an important signal pathway identified in this study, which played crucial roles in the aortic angiogenesis of AAA. There are limitations to our study. Firstly, the sample size in the IHC experiment is small and large numbers of tissue samples are needed to further validate the identified DEGs. Secondly, biological function of identified DEGs is not investigated, some in vivo or in vitro experiments are needed to further study the molecular mechanism of AAA. Thirdly, the sample size of normal individuals in the selected dataset is less than that of the patient group. In further studies, it is better to sample equal numbers of individuals in both groups in order to reduce the false positive/negative rate for up−/down-regulated DEGs detection.
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